Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Wyeth has reported worldwide net revenues of $22.8 billion for the 2008 full year, an increase of 2%, compared to $22.3 billion posted for 2007 full year.
Subscribe to our email newsletter
Net income and diluted earnings per share for the 2008 full year were $4.41 billion and $3.27, respectively, compared with $4.61 billion and $3.38, respectively, for the 2007 full year.
The company recorded worldwide net revenues of $5.3 billion for the 2008 fourth quarter, a decrease of 7%, compared to $5.7 billion reported for the corresponding period of 2007.
Net income and diluted earnings per share for the 2008 fourth quarter were $960.4 million and $0.71, respectively, compared with $1.01 billion and $0.75, respectively, for the 2007 fourth quarter.
Bernard Poussot, chairman, president and CEO of Wyeth, said: “Wyeth met its expectations in 2008 despite external pressures. Our performance was led by strong, consistent contributions from our core product franchises – Enbrel, Prevnar and Nutritionals, revenue from new products, and ongoing cost containment efforts. Our diversified revenue base helped lessen the impact of the global economic downturn and the at-risk launch of generic versions of Protonix.”